EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting
Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104
Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T Cell Activity through Integrated CD2 Costimulation
BRANFORD, Conn., April 14, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2 costimulation, today announced that new data highlighting its novel EVOLVE T cell engager platform will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is being held April 17-22, 2026, in San Diego, California.
Details of the company's presentations at the AACR conference are as follows:
Oral Minisymposium Presentation #4055:
- Title: Integrated CD2-costimulation on CD3 T cell engager EVOLVE platform yields differentiated and superior T cell effector profile
- Presenting Author: Emma Stewart, Ph.D., EvolveImmune Therapeutics
- Session Title: Advances in Therapeutic Antibodies
- Session Date/Time: Monday, April 20, 2026, 2:30 – 4:30 p.m. PT
- Location: Ballroom 20 CD – Upper Level – Convention Center
Poster Presentation #CT079:
- Title: EIU-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T cell engager, in advanced urothelial and squamous cell carcinomas
- Presenting Author: Tony Fiorino, M.D., Ph.D., EvolveImmune Therapeutics
- Session Title: Phase I Clinical Trials in Progress
- Session Date/Time: Monday, April 20, 2026, 9:00 a.m. – 12:00 p.m. PT
- Location: Poster Section 51; Poster Board #10
Poster Presentation #5594:
- Title: Pharmacological integration of CD3 and CD2 signaling triggers formation of a CD2 corolla that boosts T cell activation
- Presenting Author: Sergio Trombetta, Ph.D., EvolveImmune Therapeutics
- Session Title: T Cell Engagers 2/Antibody-Drug Conjugates 1
- Session Date/Time: Tuesday, April 21, 2026, 2:00 – 5:00 p.m. PT
- Location: Poster Section 8; Poster Board #13
About EVOLVE104
EVOLVE104 is a next-generation trispecific T cell engager that binds CD3 and CD2 on T cells and the tumor-associated antigens ULBP2/5/6, which have limited expression in normal human tissues and are found on a number of epithelial-derived malignancies, including urothelial carcinoma and a broad array of squamous cell carcinomas. In preclinical studies, EVOLVE104 has demonstrated compelling single-agent activity and combination activity with anti-PD-1 therapy, the ability to reinvigorate dysfunctional T cells, and a promising safety profile. EVOLVE104 is currently being studied in a first-in-human phase 1 clinical trial in subjects with advanced, relapsed or refractory solid tumors (NCT07217171).
About EvolveImmune Therapeutics
EvolveImmune Therapeutics, Inc. is an immuno-oncology company developing first-in-class, multi-specific T cell engagers derived from its EVOLVE platform, which have been inspired by a generation of discoveries in T cell immunology. EVOLVE molecules leverage the power of integrated CD2 costimulation to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies in a range of solid tumors and hematological cancers. The EVOLVE platform has generated a pipeline of internal and partnered programs, the most advanced of which, EVOLVE104, is in active clinical development. For more information, please visit: www.evolveimmune.com.
Contacts: EvolveImmune Therapeutics Stephen Bloch, M.D. Chief Executive Officer 860-856-7104 info@evolveimmune.com Stellar Red PR (on behalf of EvolveImmune Therapeutics) Tim Brons (Media) 646-319-8981 tbrons@stellarredPR.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
